Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001439 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
NCT00001439: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001439 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 255 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001439, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously. Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.
Interventions
- BIOLOGICAL gp100 human melanoma peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 1995-06 |
| Est. Completion | 2000-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001439
The ClinicalTrials.gov registry entry for NCT00001439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gp100 human melanoma peptide is the first listed.
NCT00001439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001439 about?
NCT00001439 is a clinical study titled "A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant". This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxi...
What is the current status of trial NCT00001439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 1995-06. Estimated completion is 2000-04.
What interventions are being tested in trial NCT00001439?
The interventions under investigation include: gp100 human melanoma peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001439?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.